Loading company…
Xellar Biosystems combines organ chip technology and AI to support drug discovery and testing.
Established in 2021, Xellar Biosystems works with pharmaceutical and biotechnology companies on drug discovery using organ chip technology and 3D cellular models. Its EPIC platform combines microfluidic organ models, cell imaging, computer vision, and artificial intelligence to assess drug safety and efficacy. In June 2026, the company raised approximately CNY 200 million in Series A+ funding to develop its 3D Bio Intelligence platform, automated experiments, Virtual Cells, and Biological World Models.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in